pulmonary hypertension - All mecanism - all patients clinical trials results meta-analysis

<h1> <a href="index.html"> <strong>pulmonary hypertension</strong> - All mecanism </a> - all patients trial results systematic overview and meta-analysis </h1> <h2>Main characteristics of the included studies</h2> <table> <tr> <th>Trial</th> <th>Treatments</th> <th>Patients</th> <th>Methods</th> </tr> <tr> <td> <a href="index.html"> Rubin, 1990 </a> <br> </td> <td> continuous intravenous infusion of epoprostenol<br>  <i>versus</i> <br> control </td> <td> patients with primary pulmonary hypertension </td> <td> follow-up 8 weeks<br> n=11/12<br> <br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Barst, 1996 </a> <br> </td> <td> continuous intravenous infusion of epoprostenol<br>  <i>versus</i> <br> control </td> <td> patients with severe primary pulmonary hypertension NYHA III or IV </td> <td> follow-up 12 weeks<br> n=41/40<br> <br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Badesch, 2000 </a> <br> </td> <td> Epoprostenol<br>  <i>versus</i> <br> control </td> <td> patients with moderate to severe pulmonary hypertension </td> <td> follow-up 12 weeks<br> n=56/55<br> <br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Channick, 2001 </a> <br> </td> <td> Bosentan<br>  <i>versus</i> <br> Placebo </td> <td> patients with pulmonary hypertension (primary or associated with scleroderma) </td> <td> follow-up 12 weeks<br> n=21/11<br> <br> double blind <br> </td> </tr> <tr> <td> <a href="index.html"> Langleben, 2002 </a> <br> </td> <td> Terbogrel<br>  <i>versus</i> <br> Placebo </td> <td> </td> <td> follow-up 12 weeks<br> n=46/25<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Simmoneau, 2002 </a> <br> </td> <td> Treprostinil<br>  <i>versus</i> <br> Placebo </td> <td> patients with pulmonary arterial hypertension, either primary or associated with connective tissue disease or congenital systemic-to-pulmonary shunts </td> <td> follow-up 12 weeks<br> n=233/237<br> <br> double blind <br> </td> </tr> <tr> <td> <a href="index.html"> ALPHABET (Galie), 2002 </a> <br> </td> <td> Beraprost<br>  <i>versus</i> <br> Placebo </td> <td> patients with pulmonary arterial hypertension NYHA II or III </td> <td> follow-up 12 weeks<br> n=65/65<br> <br> double blind <br> </td> </tr> <tr> <td> <a href="index.html"> AIR (Olschewski), 2002 </a> <br> </td> <td> repeated daily inhalations of 2.5 or 5.0 microg of iloprost (six or nine times per day; median inhaled dose, 30 microg per day)<br>  <i>versus</i> <br> Placebo </td> <td> atients with selected forms of severe pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension NYHA III or IV </td> <td> follow-up 12 weeks<br> n=101/102<br> <br> double blind <br> </td> </tr> <tr> <td> <a href="index.html"> BREATHE-1 (Rubin), 2002 </a> <br> </td> <td> Bosentan 125 or 250 mg twice daily (after 4 weeks of 62.5 mg of bosentan twice daily)<br>  <i>versus</i> <br> Placebo </td> <td> patients with pulmonary arterial hypertension (primary or associated with connective-tissue disease) </td> <td> follow-up 16 weeks<br> n=144/69<br> <br> double blind <br> </td> </tr> <tr> <td> <a href="index.html"> Barst, 2003 </a> <br> </td> <td> Beraprost<br>  <i>versus</i> <br> Placebo </td> <td> </td> <td> follow-up 36 weeks<br> n=60/56<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Sastry, 2004 </a> <br> </td> <td> sildenafil with dosages ranging from 25 to 100 mg thrice daily on the basis of body weight<br>  <i>versus</i> <br> Placebo </td> <td> patients with primary pulmonary hypertension </td> <td> follow-up 12 weeks<br> n=10/12<br> <br> double blind <br> </td> </tr> <tr> <td> <a href="index.html"> BREATH-2 (Humbert), 2004 </a> <br> </td> <td> Epoprostenol + Bosentan (62.5 mg b.i.d for 4 weeks then 125 mg b.i.d)<br>  <i>versus</i> <br> Epoprostenol + placebo </td> <td> patients with pulmonary arterial hypertension </td> <td> follow-up 16 weeks<br> n=22/11<br> <br> double blind <br> </td> </tr> <tr> <td> <a href="index.html"> STRIDE-1 (Barst), 2004 </a> <br> </td> <td> Sitaxsentan 100mg or 300 mg orally once daily for 12 weeks<br>  <i>versus</i> <br> Placebo </td> <td> patients with pulmonary arterial hypertension that was idiopathic, related to connective tissue disease or congenital heart disease </td> <td> follow-up 12 weeks<br> n=118/60<br> <br> double blind <br> </td> </tr> <tr> <td> <a href="index.html"> SUPER-1 (Galie), 2005 </a> <br> </td> <td> Sildenafil<br>  <i>versus</i> <br> Placebo </td> <td> patients with symptomatic pulmonary arterial hypertension (either idiopathic or associated with connective-tissue disease or with repaired congenital systemic-to-pulmonary shunts) </td> <td> follow-up 12 weeks<br> n=208/70<br> <br> double blind <br> </td> </tr> <tr> <td> <a href="index.html"> SERAPH (Wilkins), 2005 </a> <br> </td> <td> bosentan 62.5 mg twice daily for 4 weeks, then 125 mg twice daily<br>  <i>versus</i> <br> sildenafil 50 mg twice daily for 4 weeks, then 50 mg three times daily </td> <td> patients with PAH, idiopathic or associated with connective tissue disease </td> <td> follow-up 16 weeks<br> n=14/12<br> <br> double blind <br> </td> </tr> <tr> <td> <a href="index.html"> Singh, 2006 </a> <br> </td> <td> Sildenafil<br>  <i>versus</i> <br> Placebo </td> <td> idiopathic PAH and PAH caused by Eisenmenger syndrome </td> <td> follow-up 8 weeks<br> n=10/10<br> <br> double blind <br> </td> </tr> <tr> <td> <a href="index.html"> BREATH-5 (Galie), 2006 </a> <br> </td> <td> Bosentan<br>  <i>versus</i> <br> Placebo </td> <td> patients with World Health Organization functional class III Eisenmenger syndrome </td> <td> follow-up 16 weeks<br> n=37/17<br> <br> double blind <br> </td> </tr> <tr> <td> <a href="index.html"> STRIDE-2 (Barst), 2006 </a> <br> </td> <td> Sitaxsentan<br>  <i>versus</i> <br> Placebo </td> <td> patients with idiopathic, or associated with connective tissue disease or congenital heart disease pulmonary arterial hypertension </td> <td> follow-up 18 weeks<br> n=123/62<br> <br> open <br> </td> </tr> <tr> <td> <a href="index.html"> STEP (McLaughlin), 2006 </a> <br> </td> <td> inhaled iloprost (5 mug)<br>  <i>versus</i> <br> Placebo </td> <td> patients with PAH </td> <td> follow-up 12 weeks<br> n=34/33<br> <br> double blind <br> </td> </tr> <tr> <td> <a href="index.html"> COMBI (Hoeper), 2006 </a> <br> </td> <td> Inhaled iloprost<br>  <i>versus</i> <br> Placebo </td> <td> </td> <td> follow-up 12 weeks<br> n=19/21<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> ARIES (Galie=, 2008 </a> <br> </td> <td> ambrisentan (5, 10, 2.5 or 5 mg) orally once daily<br>  <i>versus</i> <br> Placebo </td> <td> patients with pulmonary arterial hypertension </td> <td> follow-up 12 weeks<br> n=261/133<br> <br> double blind <br> </td> </tr> <tr> <td> <a href="index.html"> EARLY (Galie), 2008 </a> <br> NCT00091715 </td> <td> Bosentan<br>  <i>versus</i> <br> Placebo </td> <td> Patients with WHO FC II pulmonary arterial hypertension </td> <td> follow-up 24 weeks<br> n=93/92<br> <br> double blind <br> </td> </tr> <tr> <td> <a href="index.html"> PACES (Simonneau), 2008 </a> <br> </td> <td> sildenafil, 20 mg three times daily, titrated to 40 mg and 80 mg three times daily, as tolerated, at 4-week intervals<br>  <i>versus</i> <br> Placebo </td> <td> patients with pulmonary arterial hypertension (idiopathic, associated anorexigen use or connective tissue disease, or corrected congenital heart disease) </td> <td> follow-up 16 weeks<br> n=134/133<br> <br> double blind <br> 11 countries </td> </tr> <tr> <td> <a href="index.html"> FREEDOM-C2, </a> <br> NCT00887978 </td> <td> Oral UT-15C Sustained Release<br>  <i>versus</i> <br> placebo </td> <td> subjects with PAH who are currently receiving approved therapy for their PAH (i.e., endothelin receptor antagonist and/or phosphodiesterase-5 inhibitor). </td> <td> follow-up 16 weeks<br> n=-9/-9<br> Parallel groups<br> double blind <br> </td> </tr> </table> <h2>References</h2> <p> <b>Rubin, 1990 : </b> Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB, Diehl JH, Crow J, Long W <i>Ann Intern Med 1990;112:485-91</i> [PMID 2107780] </p> <p> <b>Barst, 1996 : </b> Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH <i>N Engl J Med 1996;334:296-302</i> [PMID 8532025] </p> <p> <b>Badesch, 2000 : </b> Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, Rich S, Barst RJ, Barrett PS, Kral KM, J�bsis MM, Loyd JE, Murali S, Frost A, Girgis R, Bourge RC, Ralph DD, Elliott CG, Hill NS, Langleben D, Schilz RJ, McLaughlin VV, Robbins IM, Groves <i>Ann Intern Med 2000;132:425-34</i> [PMID 10733441] </p> <p> <b>Channick, 2001 : </b> Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Bodin F, Rubin LJ <i>Lancet 2001;358:1119-23</i> [PMID 11597664] 10.1016/S0140-6736(01)06250-X </p> <p> <b>Langleben, 2002 : </b> Langleben D, Christman BW, Barst RJ, Dias VC, Gali� N, Higenbottam TW, Kneussl M, Korducki L, Naeije R, Riedel A, Simonneau G, Hirsch AM, Rich S, Robbins IM, Oudiz R, McGoon MD, Badesch DB, Levy RD, Mehta S, Seeger W, Sol�r M <i>Am Heart J 2002;143:E4</i> [PMID 12040360] </p> <p> <b>Langleben, 2002 : </b> Langleben D, Christman BW, Barst RJ, Dias VC, Gali� N, Higenbottam TW, Kneussl M, Korducki L, Naeije R, Riedel A, Simonneau G, Hirsch AM, Rich S, Robbins IM, Oudiz R, McGoon MD, Badesch DB, Levy RD, Mehta S, Seeger W, Sol�r M <i>Am Heart J 2002;143:E4</i> [PMID 12040360] </p> <p> <b>Simmoneau, 2002 : </b> Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, Blackburn SD, Crow JW, Rubin LJ <i>Am J Respir Crit Care Med 2002;165:800-4</i> [PMID 11897647] </p> <p> <b>ALPHABET (Galie), 2002 : </b> Gali� N, Humbert M, Vachi�ry JL, Vizza CD, Kneussl M, Manes A, Sitbon O, Torbicki A, Delcroix M, Naeije R, Hoeper M, Chaouat A, Morand S, Besse B, Simonneau G <i>J Am Coll Cardiol 2002;39:1496-502</i> [PMID 11985913] </p> <p> <b>AIR (Olschewski), 2002 : </b> Olschewski H, Simonneau G, Gali� N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani HA, Manes A, Kiely DG, Ewert R, Meyer A, Corris PA, Delcroix M, Gomez-Sanchez M, Siedentop H, Seeger W <i>N Engl J Med 2002;347:322-9</i> [PMID 12151469] 10.1056/NEJMoa020204 </p> <p> <b>BREATHE-1 (Rubin), 2002 : </b> Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G <i>N Engl J Med 2002;346:896-903</i> [PMID 11907289] 10.1056/NEJMoa012212 </p> <p> <b>Barst, 2003 : </b> Barst RJ, McGoon M, Mc Laughlin VV, Tapson V, Rich S, Rubin L, Wasserman K, <i>J Am Coll Cardiol 2003;41:2125</i> [PMID ] </p> <p> <b>Sastry, 2004 : </b> Sastry BK, Narasimhan C, Reddy NK, Raju BS <i>J Am Coll Cardiol 2004;43:1149-53</i> [PMID 15063421] 10.1016/j.jacc.2003.10.056 </p> <p> <b>BREATH-2 (Humbert), 2004 : </b> Humbert M, Barst RJ, Robbins IM, Channick RN, Gali� N, Boonstra A, Rubin LJ, Horn EM, Manes A, Simonneau G <i>Eur Respir J 2004;24:353-9</i> [PMID 15358690] 10.1183/09031936.04.00028404 </p> <p> <b>STRIDE-1 (Barst), 2004 : </b> Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, McLaughlin V, Hill N, Tapson VF, Robbins IM, Zwicke D, Duncan B, Dixon RA, Frumkin LR <i>Am J Respir Crit Care Med 2004;169:441-7</i> [PMID 14630619] 10.1164/rccm.200307-957OC </p> <p> <b>SUPER-1 (Galie), 2005 : </b> Gali� N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G <i>N Engl J Med 2005;353:2148-57</i> [PMID 16291984] 10.1056/NEJMoa050010 </p> <p> <b>SERAPH (Wilkins), 2005 : </b> Wilkins MR, Paul GA, Strange JW, Tunariu N, Gin-Sing W, Banya WA, Westwood MA, Stefanidis A, Ng LL, Pennell DJ, Mohiaddin RH, Nihoyannopoulos P, Gibbs JS <i>Am J Respir Crit Care Med 2005;171:1292-7</i> [PMID 15750042] 10.1164/rccm.200410-1411OC </p> <p> <b>Singh, 2006 : </b> Singh TP, Rohit M, Grover A, Malhotra S, Vijayvergiya R <i>Am Heart J 2006;151:851.e1-5</i> [PMID 16569546] 10.1016/j.ahj.2005.09.006 </p> <p> <b>BREATH-5 (Galie), 2006 : </b> Gali� N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, Chiossi E, Landzberg M <i>Circulation 2006;114:48-54</i> [PMID 16801459] 10.1161/CIRCULATIONAHA.106.630715 </p> <p> <b>STRIDE-2 (Barst), 2006 : </b> Barst RJ, Langleben D, Badesch D, Frost A, Lawrence EC, Shapiro S, Naeije R, Galie N <i>J Am Coll Cardiol 2006;47:2049-56</i> [PMID 16697324] 10.1016/j.jacc.2006.01.057 </p> <p> <b>STEP (McLaughlin), 2006 : </b> McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, Badesch DB, Barst RJ, Hsu HH, Rubin LJ <i>Am J Respir Crit Care Med 2006;174:1257-63</i> [PMID 16946127] 10.1164/rccm.200603-358OC </p> <p> <b>COMBI (Hoeper), 2006 : </b> Hoeper M, Leuchte H, Halank M, Wilkens H, Meyer FJ, Seifarth HJ, Wensel R, <i>Eur Resp J 2006;4:691�694</i> [PMID ] </p> <p> <b>ARIES (Galie=, 2008 : </b> Gali� N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Gerber MJ, Dufton C, Wiens BL, Rubin LJ <i>Circulation 2008;117:3010-9</i> [PMID 18506008] 10.1161/CIRCULATIONAHA.107.742510 </p> <p> <b>EARLY (Galie), 2008 : </b> Gali� N, Rubin Lj, Hoeper M, Jansa P, Al-Hiti H, Meyer G, Chiossi E, Kusic-Pajic A, Simonneau G <i>Lancet 2008;371:2093-100</i> [PMID 18572079] 10.1016/S0140-6736(08)60919-8 </p> <p> <b>PACES (Simonneau), 2008 : </b> Simonneau G, Rubin LJ, Gali� N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, Cossons N, Sitbon O, Badesch DB <i>Ann Intern Med 2008;149:521-30</i> [PMID 18936500] </p>